Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $128 | $112 | $134 |
| % Growth | -99.3% | 13.6% | -16.3% | – |
| Cost of Goods Sold | $0 | $37 | $45 | $46 |
| Gross Profit | $1 | $91 | $67 | $88 |
| % Margin | 73% | 71% | 59.7% | 65.9% |
| R&D Expenses | $0 | $36 | $43 | $38 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $0 | $31 | $32 | $35 |
| Sales & Mktg Exp. | $0 | $0 | $31 | $0 |
| Other Operating Expenses | $0 | $1 | $3 | -$0 |
| Operating Expenses | $0 | $69 | $78 | $74 |
| Operating Income | $0 | $22 | -$11 | $15 |
| % Margin | 23% | 17.2% | -9.8% | 11.1% |
| Other Income/Exp. Net | -$0 | $1 | -$2 | $3 |
| Pre-Tax Income | $0 | $23 | -$13 | $17 |
| Tax Expense | $0 | $5 | -$6 | $3 |
| Net Income | $0 | $18 | -$7 | $15 |
| % Margin | 17.4% | 13.9% | -5.8% | 11.1% |
| EPS | 0.32 | 37.62 | -13.93 | 31.83 |
| % Growth | -99.1% | 370.1% | -143.8% | – |
| EPS Diluted | 0.32 | 37.58 | -13.97 | 31.81 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $3 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $0 | $9 | $9 | $9 |
| EBITDA | $0 | $31 | -$6 | $24 |
| % Margin | 30.9% | 24.5% | -5.2% | 17.9% |